Arrhythmia Medical Services in China

Arrhythmia refers to abnormal electrical activity in the heart, resulting in irregular, too fast (tachyarrhythmias such as atrial fibrillation or ventricular tachycardia), too slow (bradycardia), or erratic heart rhythms. These disturbances may originate from the sinoatrial node, atrioventricular node, or ventricular myocardium and can impair cardiac output, increase thromboembolic risk—particularly stroke in atrial fibrillation—or precipitate hemodynamic instability and sudden cardiac death. Diagnosis relies on electrocardiography (ECG), Holter monitoring, event recorders, electrophysiological studies (EPS), and advanced imaging including cardiac MRI and CT angiography. Management spans pharmacotherapy (antiarrhythmics, anticoagulants), catheter ablation (radiofrequency or cryoablation), device implantation (pacemakers, ICDs), and surgical interventions like maze procedures.

China offers distinct advantages for arrhythmia care: its tier-1 cardiovascular centers—such as Fuwai Hospital and Shanghai Ruijin Hospital—host internationally trained electrophysiologists with extensive experience in complex ablations and hybrid procedures. State-of-the-art infrastructure includes 3D electroanatomic mapping systems (CARTO, EnSite), robotic-assisted ablation platforms, and real-time intracardiac echocardiography. Clinical outcomes align with global benchmarks: >92% success rates for paroxysmal AF ablation and >85% for persistent forms, supported by robust long-term follow-up data. Crucially, treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising quality—due to streamlined healthcare financing and high-volume procedural efficiency.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital accreditation, coordinating EPS scheduling and multidisciplinary consultations, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and accommodation to post-procedure rehabilitation coordination and telemedicine follow-up.

Treatment Options & Itemized Cost Breakdown: Arrhythmia (Cardiology Department)

Non-Surgical / Conservative Management

*Target Criteria:* Asymptomatic or mild symptomatic arrhythmias (e.g., occasional PACs/PVCs), stable atrial fibrillation with controlled ventricular rate, or patients unfit for intervention.

• •Initial Diagnostic Workup

- 24-h Holter monitoring: $45–$65 - Transthoracic echocardiogram (TTE): $75–$110 - Basic labs (CBC, electrolytes, TSH, renal function): $35–$50

• •Pharmacotherapy (Monthly, Tiered)

- *Tier 2 (Brand-name or newer agents)*: Dronedarone, flecainide, or rivaroxaban (for AFib stroke prevention) — $45–$95 - *Tier 3 (Specialized antiarrhythmics with monitoring)*: Sotalol + mandatory ECG/QT monitoring every 2 weeks — $65–$120/month (includes follow-up ECGs at $12 each)

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* Symptomatic drug-refractory arrhythmia, high-risk features (e.g., LVEF <35%, syncope, VT/VF history), or paroxysmal/persistent AFib meeting CHA₂DS₂-VASc ≥2 and HAS-BLED ≤2.

• •Catheter Ablation (Radiofrequency or Cryo)

- Procedure fee (AFib ablation): $3,200–$4,800 - VT ablation (complex substrate mapping): $4,500–$6,300 - Hospital stay (3–5 days, Grade 3A ward): $420–$680

• •Implantable Devices

- ICD implantation (transvenous): $7,900–$9,600 - Subcutaneous ICD (S-ICD): $11,200–$13,500

Special / Complex Condition Management

• •Atrial Fibrillation with Structural Heart Disease (e.g., severe mitral regurgitation): Combined surgical maze + valve repair — $14,800–$18,300
• •Brugada Syndrome or CPVT with high genetic risk: Quinidine + ICD + genetic counseling — $1,200–$1,800/year (monitoring + meds)
• •Electrophysiology Study (EPS) with programmed stimulation: $1,900–$2,600 (diagnostic only, no ablation)

Quick Selection Guide

• •<60 years, active, symptomatic AFib: Catheter ablation ($3,200–$4,800) — highest long-term cost-effectiveness.
• •≥75 years, multiple comorbidities (COPD, CKD), asymptomatic PVCs: Tier 1 pharmacotherapy ($8–$15/month) + annual Holter/TTE.
• •Young patient with recurrent VT & ischemic cardiomyopathy: ICD implantation ($7,900–$9,600) + guideline-directed medical therapy.
• •Budget-constrained (<$500 total): Comprehensive diagnostics ($200–$300) + Tier 1 meds — avoid ablation or devices unless life-threatening.
• •LVEF <30% + sustained VT: ICD + amiodarone + EPS-guided ablation — bundled cost $12,500–$15,200.